Trending...
- Tampa-Based Digital Marketing Agency Launches New Website to Help Local Businesses Grow Online
- Global Families Turn to Young Travelers Concierge Amid Rising Safety Concerns in the U.S
- DuoKey to Unveil Encrypted Financial Intelligence Use Case at GISEC Global 2025
SHANGHAI, May 28, 2023 ~ Abbisko Therapeutics Co., Ltd. has announced that the updated results of their Phase Ib study of their CSF-1R inhibitor Pimicotinib (ABSK021) in treating patients with advanced tenosynovial giant cell tumor ("TGCT") will be released at the 2023 American Society of Clinical Oncology ("ASCO") annual meeting to be held in Chicago, USA from June 2 to June 6, 2023.
The data demonstrates the excellent antitumor efficacy and safety profile of Pimicotinib in the treatment of patients with advanced TGCT and will be presented with the title of "EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE" in a poster presentation with the poster Bd# of "493".
The most remarkable result is the objective response rate (ORR) of the 50 mg QD dose group of Pimicotinib (ABSK021), which reached 77.4% (24/31), including two complete responses (CR) and 22 partial responses (PR). Additionally, 87.5% (21/24) of patients with objective response were observed within the first 25 weeks. Furthermore, Pimicotinib also presented apparent advantages in terms of safety profile.
More on illi News
Currently, Pexidartinib developed by Daiichi Sankyo is the only drug approved for the treatment of TGCT in the global market. However, it has been given a "black box warning" by the FDA due to potential risk of fatal liver damage and its objective response rate is only 38%. Despite this, Daiichi Sankyo achieved sales of approximately US$40 million in the global market with Pexidartinib. CICC predicts that the global market for TGCT could amount to around 1 billion US dollars.
In comparison to Pexidartinib from Daiichi Sankyo, Abbisko's Pimicotinib shows better efficacy and safety in treating TGCT and is expected to become a best-in-class drug. If approved for use on TGCT in 2025 with a market penetration rate of 20%, its peak sales are estimated to reach 3.14 billion yuan (after risk adjustment) with listing price reference to Pexidartinib at $250,000 per year.
The data demonstrates the excellent antitumor efficacy and safety profile of Pimicotinib in the treatment of patients with advanced TGCT and will be presented with the title of "EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): PHASE 1B UPDATE" in a poster presentation with the poster Bd# of "493".
The most remarkable result is the objective response rate (ORR) of the 50 mg QD dose group of Pimicotinib (ABSK021), which reached 77.4% (24/31), including two complete responses (CR) and 22 partial responses (PR). Additionally, 87.5% (21/24) of patients with objective response were observed within the first 25 weeks. Furthermore, Pimicotinib also presented apparent advantages in terms of safety profile.
More on illi News
- Mentor Agile Empowers Illinois Residents with Free Access To Product Management Training
- Midwest Pond Features & Landscapes Hits 100 Cleanouts This Spring, Expands Services Across Chicago
- Aureli Construction Sets the Standard for Seamless Home Additions in Greater Boston
- ScreenPoints Puts Film Investors in the Credits—and in the Money With New FinTech Platform
- Beyond Finance Wins Gold Stevie® Award for Customer Service Department of the Year in 23rd Annual American Business Awards
Currently, Pexidartinib developed by Daiichi Sankyo is the only drug approved for the treatment of TGCT in the global market. However, it has been given a "black box warning" by the FDA due to potential risk of fatal liver damage and its objective response rate is only 38%. Despite this, Daiichi Sankyo achieved sales of approximately US$40 million in the global market with Pexidartinib. CICC predicts that the global market for TGCT could amount to around 1 billion US dollars.
In comparison to Pexidartinib from Daiichi Sankyo, Abbisko's Pimicotinib shows better efficacy and safety in treating TGCT and is expected to become a best-in-class drug. If approved for use on TGCT in 2025 with a market penetration rate of 20%, its peak sales are estimated to reach 3.14 billion yuan (after risk adjustment) with listing price reference to Pexidartinib at $250,000 per year.
Filed Under: Business
0 Comments
Latest on illi News
- Robert Fabbio Inducted into the Austin Technology Council Hall of Fame
- Mayor Brandon Johnson Appoints Francisco Velez as Executive Director of the Chicago Office of Emergency Management and Communications
- Chicago City Council Passes Mayor Johnson's Landmark Green Social Housing Ordinance
- Cybersecurity is Protecting Your Personal Information and Your Portfolio
- Transfer Pricing Expert Andrew O'Brien-Penney Joins The Brattle Group as Principal
- Naperville Fire Department Invites Community Members to Fire Prevention Presentation on May 22
- L2 Aviation Celebrates Grand Opening of New Facility at Cincinnati/Northern Kentucky International Airport (CVG)
- Managing Summer Staffing Surges with Confidence: Why Name Badges Are a Must for Seasonal Success
- DR Instruments Inc Expands Lab Apparel Line with New 100% Cotton Lab Coats for Adults and Youth
- Visa Named Title Sponsor of Ascending Athletes' Business Owners Summits for NFL Entrepreneurs
- The Paris Court of International Arbitration Elects Dr. John J. Maalouf as its New President
- Powerhouse Dynamics to Showcase Groundbreaking OilSmart by Open Kitchen® Solution at National Restaurant Association Show
- $56.7 Million Announced in Q1 2025 with Revenue Growth and Progress Toward NASDAQ Uplisting for AI Marketing Company: IQSTEL, Inc. Stock Symbol: IQSTD
- SAVVY MINING raised $500 million and launched BTC.XRP.DOGE cloud mining, increasing investors' returns by 30%
- New National Nonprofit Launches to Capture Firsthand Accounts of Adoption Stories
- The Tide Project Opens at Biennale Architettura 2025 in Venice Amplifying Youth Voices
- Wall Street analysts say BTC.XRP.DOGE cloud mining company SIX MINING is expected to achieve a 5-fold increase, allowing users to easily mine BTC
- Gen X Takes The Reins: New Book Guides Caregivers Juggling Parents, Kids, And Grandkids With Humor And Heart
- Naperville Welcomes Top Global Leaders Through Americas Competitiveness Exchange Visit
- Fray Fitness Launches Memorial Day Sale and Veteran Organization Giveaway